Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment.
1. A method of preventing evolution to chronic infection of a HCV infection in a mammal comprising administering an effective amount of a prophylactic HCV composition prior to said HCV infection, said composition comprising a prophylactically effective amount of at least one HCV envelope E1 protein or a part thereof; and at least one of a pharmaceutically acceptable carrier, adjuvant or vehicle wherein said HCV envelope E1 protein or part thereof is a single or specific oligomeric protein not disulfide linked with contaminants.
2. A method of preventing evolution to chronic infection of a HCV infection in a mammal comprising administering an effective amount of a prophylactic HCV composition prior to said HCV infection, said composition comprising a prophylactically effective amount of a combination of at least two HCV envelope E1 proteins or parts thereof wherein said at least two E1 proteins or parts thereof are single or specific oligomeric proteins not disulfide linked with contaminants and are derived from different HCV genotypes, subtypes or isolates; and at least one of a pharmaceutically acceptable carrier, adjuvant or vehicle.
3. The method according to claim 2 wherein said HCV infection is an infection with a HCV of a genotype or subtype homologous or heterologous to the HCV genotype or subtype, or HCV genotypes or subtypes, from which the E1 protein or part thereof comprised in said composition are derived.
4. The method according to claim 1 wherein said mammal is a human.
5. The method according to claim 2 wherein said mammal is a human.
6. The method according to claim 1 or 2 wherein said E1 protein is E1s.
7. The method according to claim 1 or 2 wherein said E1 protein or part thereof is produced by a recombinant host.
8. The method according to claim 7 wherein said recombinant host is a recombinant mammalian cell, a recombinant yeast cell or a recombinant virus.
9. The method according to claim 1 or 2 wherein the cysteines of said HCV envelope E1 proteins or parts thereof are blocked.
10. The method according to claim 1 or 2 wherein said HCV envelope E1 proteins or parts thereof are in the form of particles.
11. A method of preventing evolution to chronic infection of a HCV infection in a mammal comprising administering an effective amount of a prophylactic HCV composition prior to said HCV infection, said composition consisting of a prophylactically effective amount of at least one HCV envelope E1 protein or a part thereof; and at least one of a pharmaceutically acceptable carrier, adjuvant or vehicle wherein said HCV envelope E1 protein or part thereof is a single or specific oligomeric protein not disulfide linked with contaminants.
12. The method according to claim 11 wherein said mammal is a human.
13. The method according to claim 11 wherein said E1 protein is E1s.
14. The method according to claim 11 wherein said E1 protein or part thereof is produced by a recombinant host.
15. The method according to claim 14 wherein said recombinant host is a recombinant mammalian cell, a recombinant yeast cell or a recombinant virus.
16. The method according to claim 11 wherein the cysteines of said HCV envelope E1 proteins or parts thereof are blocked.
17. The method according to claim 11 wherein said HCV envelope E1 proteins or parts thereof are in the form of particles.